SCHEMBL19689487

SCHEMBL19689487

N#Cc1ccnc(N2CC(O)(c3ccc(O)cc3Cl)C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.40
PANK3 Q9H999 1/20 0.38
PDGFRB P09619 1/20 0.38
KDR P35968 1/20 0.38
PPARG P37231 1/20 0.37
NR1H4 Q96RI1 3/20 0.37
HSD17B13 Q7Z5P4 1/20 0.37
HRH3 Q9Y5N1 1/20 0.35
CHRM4 P08173 1/20 0.35
LCAT P04180 1/20 0.35
CCR2 P41597 1/20 0.34
HTR7 P34969 1/20 0.33
HCRTR1 O43613 3/20 0.33
HCRTR2 O43614 3/20 0.33
USP30 Q70CQ3 1/20 0.33
CYP19A1 P11511 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CNR2 P34972 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30064306 1.00 MALT1 (0.40) MALT1PANK3PDGFRBKDRPPARG
SCHEMBL17843296 0.89 MALT1 (0.43) MALT1PANK3PDGFRBKDRPPARG
SCHEMBL19690236 0.84 SMO (0.41) PANK3PPARGNR1H4CHRM4CYP19A1
SCHEMBL30064297 0.80 NR1H4 (0.39) MALT1PANK3PPARGNR1H4HSD17B13
SCHEMBL19689544 0.80 NR1H4 (0.39) MALT1PANK3PPARGNR1H4HSD17B13
SCHEMBL29139872 0.79 NR1H4 (0.53) NR1H4HSD17B13
SCHEMBL30775159 0.79 NR1H4 (0.53) NR1H4HSD17B13
SCHEMBL28924291 0.77 CTSS (0.39) NR1H4HSD17B13LCATESR1ESR2
SCHEMBL19690321 0.76 NR1H4 (0.40) NR1H4CHRM4CYP19A1
SCHEMBL19202591 0.76 NR1H4 (0.45) NR1H4HSD17B13HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4534536-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2025-04-09 EP disclosed
EP-4089072-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2024-08-28 EP disclosed
US-11739065-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2023-08-29 US disclosed
US-11739065-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2023-08-29 US disclosed
EP-4089072-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2022-11-16 EP disclosed
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-06-30 US disclosed
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS PHENEX PHARMACEUTICALS AG (DE) 2022-06-30 US disclosed
EP-3587412-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2022-05-25 EP disclosed
US-10981881-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2021-04-20 US disclosed
US-10981881-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2021-04-20 US disclosed
US-10421730-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-09-24 US disclosed
US-10421730-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2019-09-24 US disclosed
EP-3257847-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
EP-3257847-B1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-08-21 EP disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
WO-2017218330-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2017-12-21 WO disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
EP-3257847-A1 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2017-12-20 EP disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981881-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 MALT1 2190/4885PANK3 2412/4885PDGFRB 2141/4885
US-11739065-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 MALT1 2190/4885PANK3 2412/4885PDGFRB 2141/4885
US-10421730-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 MALT1 2190/4885PANK3 2412/4885PDGFRB 2141/4885
US-20170355685-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MALT1 2190/4885PANK3 2412/4885PDGFRB 2141/4885
US-20220204460-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 MALT1 2190/4885PANK3 2412/4885PDGFRB 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.